In addition, the tumour AT2 cells were noted to express more LYPD3 compared to background AT2 cells (log2FC = 2.04, Padj = 0.039, Supplementary Data 16), an adhesion protein which has previously been connected to poor prognosis in NSCLC and is currently being targeted in preclinical and clinical studies41,42. The gene discussed is LYPD3; the disease is neoplasm.